Compare Gilead Sciences, Inc. (GILD) vs Snowflake Inc (SNOW) Price & Performance

Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).

Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.

Snowflake (SNOW) trades at $332.85, down 0.92% on the day, as the stock shows mixed technical signals with neutral overall momentum. Fundamentally, the company demonstrates strong revenue growth reaching $3.63 billion in 2025 but continues to post significant losses with a -20.07% net margin. Recent positive developments include three consecutive earnings beats and a strategic partnership expansion with UiPath, though the company faces investor concerns over a $3.75 billion convertible note offering announced in late September 2026.

Wall Street maintains strong bullish sentiment with 81% buy ratings and a $418.03 consensus price target representing 26% upside potential. The investment case hinges on Snowflake's position in the growing data cloud market and improving revenue trajectory, balanced against persistent profitability challenges and competitive pressures in the enterprise software sector.